Skip to main content
Figure 6 | Respiratory Research

Figure 6

From: Efficacy and safety of fixed-dose combinations of aclidinium bromide/formoterol fumarate: the 24-week, randomized, placebo-controlled AUGMENT COPD study

Figure 6

Improvements in TDI focal score as assessed by (A) mean changes from baseline at week 24, (B) percentage of patients who responded at week 24, and (C) percentage of patients who responded over time. Mean changes were analyzed using a mixed-model for repeated measures. Responders were defined as patients who had a TDI focal score improvements of ≥1 unit; ORs based on a logistic random effect model for active treatment versus placebo. *p< 0.01 versus placebo; **p ≤ 0.001 versus placebo; †p< 0.05 versus aclidinium and placebo; ‡p< 0.05 versus formoterol and placebo. ACL400/FOR12 FDC, fixed-dose combination of aclidinium 400μg and formoterol 12μg; ACL400/FOR6 FDC, fixed-dose combination of aclidinium 400μg and formoterol 6μg; LS, least squares; OR, odds ratio; TDI, Transition Dyspnea Index.

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us